A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma. READ MORE
A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma.
A novel triplet regimen had the largest progression-free survival benefit compared with three other triplet regimens for patients with relapsed or refractory multiple myeloma.
A recent study confirmed that administering a higher dosage once-weekly of a common therapy for relapsed or refractory multiple myeloma improves PFS by 3.6 months, compared with twice-weekly administration of a lower dosage.
Researchers developed a novel gene signature that has prognostic value in patients with multiple myeloma who are treated with immunomodulatory derivatives.
Recent research has uncovered a non-inferior, cost-effective alternative to standard therapy for autologous stem cell mobilization in multiple myeloma. The study’s author discusses his findings.
The National Comprehensive Cancer Network has implemented categories of preference for recommendations within their clinical practice guidelines in oncology.